摘要
目的分析手术去势与药物去势治疗前列腺癌的临床治疗效果。方法选取45例前列腺癌患者作为研究对象,其中给予手术去势的22例患者为对照组,给予亮丙瑞林药物去势的23例患者为观察组,两组患者均联合比卡鲁胺行全雄激素阻断(每4周为一个周期,每天皮下注射1次),治疗6个周期后,对比治疗后两组患者的临床疗效和不良反应。结果治疗后对照组和观察组患者的治疗有效率分别为86.4%(19/22)和91.3%(21/23),但差异无统计学意义(P﹥0.05);治疗6个周期后对照组患者和观察组患者的血清睾酮水平维持在去势水平的比例分别为91.3%(21/23)和86.4%(19/22),差异无统计学意义(P﹥0.05);治疗后两组患者均出现潮热、胸部胀痛、疲劳、出汗等不良反应,两组差异有统计学意义(P﹤0.05)。结论亮丙瑞林药物去势与手术去势疗效相当,且不良反应少,进而避免手术去势给患者带来的风险、创伤和痛苦,具有广泛推广的价值。
Objective To study the clinical effect of surgical castration and medical castration for the treatment of prostate cancer. Method 45 patients with prostate cancer were enrolled in this study with 22 patients in control group that were administered with surgical castration, and 23 patients in study group that were given leuprorelin as medical cas-tration, besides, bicalutamide was applied in both groups for total androgen blockade （given as subcutaneous injection once daily, with 4 weeks as a cycle）. After 6 cycles, efficacy and adverse reaction of the two groups were compared. Re-sult The response rate after treatment was 86.4%（19/22） in control group and 91.3%（21/23） in study group （P〉0.05）. Af-ter 6 cycles, the patients with plasma testosterone concentration remained at the level of castration accounted for 91.3%（21/23） in the control group and 86.4%（19/22） in the study group （P〉0.05）. The following adverse reactions were similar-ly observed in both groups, such as hot flash, swollen breast, fatigue and sweating （P〈0.05）. Conclusion As compared with surgical castration, medical castration with leuprorelin is comparable in regard of efficacy, which may avoid the inev-itable risk, wound, and pain in surgical castration, making it a clinically practicable therapy.
出处
《癌症进展》
2016年第4期363-365,共3页
Oncology Progress
关键词
前列腺癌
手术去势
药物去势
临床疗效
prostate cancer
surgical castration
medical castration
clinical efficacy
